AI-generated analysis. Always verify with the original filing.
Immix Biopharma, Inc. entered into Amendment No. 1 to its At The Market Offering Agreement dated June 3, 2025, with Citizens JMP Securities, LLC on March 25, 2026, permitting the Company to offer and sell up to $100,000,000 of common stock through the sales agent in an at-the-market offering. The amendment aligns with the Company's Form S-3 registration statement (File No. 333-292665) and includes a 3.0% commission and expense reimbursement up to $50,000.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 5.1 Opinion of Blank Rome LLP 10.1 At The Market Offering Agreement, dated June 3, 2025
Material Agreement